Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease (NCT05996627)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. At least one diagnostic or distinctive cGVHD manifestation(s), with a clinical diagnosis of cGVHD,but patients do not need to meet National Institute of Health (NIH) criteria for cGVHD
2. If eye involvement only, cGVHD must be confirmed on exam by an ophthalmologist or optometrist
3. No new immune suppressive therapy added within preceding 2 weeks prior to study enrollment for any indication
4. Continuation of agents previously given as either GVHD prophylaxis or acute/late acute GVHD therapy are permitted. Modification of dose of these agents for targeting of therapeutic drug levels is permitted, as are decreases in existing prednisone or prednisone equivalent dose based on routine clinical tapering practices. Increases in prednisone or prednisone equivalents are not allowed in the 2 weeks prior to enrollment
5. Age 18 and older
6. Karnofsky performance score \>= 70
7. Able to take oral medications
8. Signed informed consent
9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x upper limit of normal (ULN)
10. Total bilirubin =\< 1.5 x ULN, unless due to Gilbert's disease
11. Glomerular filtration rate (estimated glomerular filtration rate \[eGFR\]) \>= 30 mL/min/1.73 m\^2
12. Female subjects of childbearing potential have a negative serum or urine pregnancy test at screening. Females of childbearing potential are defined as sexually mature females without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, females who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (5 Sites)

• City of Hope — Duarte, California
• Moffitt Cancer Center — Tampa, Florida
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Memorial Sloan Kettering Cancer Center — New York, New York
• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.